Qingdao Haier Biomedical Co., Ltd. Class A

Qingdao Haier Biomedical Co., Ltd. Class A

SSSE:688139
33.80
CNY
+2.21
(+7.00%)
0.74EPS
35.71P/E
8.36BMarket Cap
Mar 29Next Earn
Qingdao Haier Biomedical Co., Ltd. Class A
SSE:688139
(Shanghai Stock Exchange)

Recent

price

33.80

P/E

ratio

35.71

div

yld

2.36%

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.82
3.6
4.14
4.06
4.42
6.72
9.01
7.19
7.23
7.43
7.55
Revenue per Share
0.72
0.35
0.56
0.73
1.2
2.67
1.89
1.28
1.16
0.8
0.74
Basic EPS, GAAP
1.21
0.7
0.39
0.45
1.91
1.22
1.06
0.23
0.52
0.47
- -
Free Cash Flow per Basic Share
- -
- -
1.2
0.1
0.18
0.38
0.51
0.45
0.52
0.47
0.8
Dividend per Share
3.04
2.59
4.67
7.74
8.75
11.43
12.65
13.31
13.75
13.76
13.97
Book Value per Share
2.99
2.45
4.48
7.59
7.06
9.64
10.24
10.13
10.1
10.24
10.51
Tangible Book Value per Share
171
173
203
249
317
316
318
317
316
313
314
Basic Weighted Avg Shares
482
621
842
1,013
1,402
2,126
2,864
2,281
2,284
2,329
2,370
Sales/Revenue/Turnover
26.55
10.06
12.93
20.6
22.95
21.8
20.76
14.71
15.03
10.06
8.95
Operating Margin (%)
9
9
11
11
23
51
64
103
121
126
- -
Depreciation Expense
123
60
114
182
381
845
601
406
367
251
232
Net Income, GAAP
14.19
28.34
17.58
13.14
9.46
11.62
9.38
5.16
5.21
3.64
3.65
Effective Tax Rate (%)
25.56
9.72
13.54
17.98
27.17
39.75
20.98
17.8
16.05
10.77
9.8
Profit Margin (%)
638
496
810
2,016
1,688
2,313
2,304
1,594
1,630
1,573
1,751
Working Capital
- -
- -
- -
- -
6
4
11
9
7
5
3
LT Debt
723
615
1,114
2,459
2,785
3,639
4,148
4,440
4,618
4,623
4,669
Total Equity
- -
8.62
9.55
8.96
14.41
25.79
15.46
9.52
8.3
5.46
4.85
Return on Invested Capital (%)
- -
9.41
12.24
8.75
14.29
26.05
15.11
9.32
7.8
5.34
4.95
Return on Capital (%)
- -
9.03
13.22
10.22
14.57
26.41
15.72
9.84
8.52
5.73
5.23
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
91
90
91
LT Borrowings
- -
- -
- -
LT Finance Leases
5
5
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
318
316
316
Market Capitalization
10,105
9,878
8,362

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,659
2,741
2,806
Cash, Cash Equivalents & STI
1,291
1,479
1,551
Accounts Receivable, Net
404
505
411
Inventories
345
337
334
Total Current Liabilities
1,085
1,068
1,055
Payables & Accruals
- -
- -
- -
ST Debt
91
90
91
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
11.17%
0.11%
Free Cash Flow
- -
-1.73%
-9.89%
Net Income, GAAP
- -
3.84%
-31.61%
Sales/Revenue/Turnover
- -
13.62%
1.96%
Total Cash Common Dividend
- -
27.64%
-9.65%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
687
536
559
502
2,284
2025
689
507
- -
567
2,329
2026
652
644
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.44
0.31
0.24
0.18
1.16
2025
0.35
0.1
- -
0.17
0.8
2026
0.25
0.22
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.52
- -
- -
0.52
2025
- -
0.47
- -
- -
0.47
2026
- -
0.33
- -
- -
- -
Business
Qingdao Haier Biomedical Co., Ltd. is a China-based company primarily engaged in the research, development, manufacturing, and commercialization of biomedical low-temperature storage equipment and comprehensive Internet of Things (IoT)-driven digital solutions for the life sciences and healthcare sectors. Founded in 2005 and headquartered in Qingdao, Shandong Province, China, the company operates as a key member of Haier Group Corporation and is publicly listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. The company operates across two core business segments, Life Sciences and Medical Innovation, offering an extensive portfolio of products and systematic solutions: biomedical cold storage and cryogenic equipment, including ultra-low temperature freezers, cryogenic storage systems, biomedical freezers, laboratory and pharmacy refrigerators, blood bank refrigerators, ice-lined refrigerators, solar direct drive (SDD) vaccine refrigerators, and liquid nitrogen storage systems; biosafety and general laboratory equipment, including Class II and Class III biological safety cabinets, clean benches, carbon dioxide incubators, centrifuges, autoclaves, freeze dryers, and laboratory water purification systems; IoT-integrated healthcare scenario solutions, including smart blood management networks connecting blood collection, cold chain transit, and clinical transfusion; smart vaccination solutions comprising automated vaccination clinics, mobile vaccination vehicles, and real-time cold chain monitoring networks; automated biobanking solutions featuring robotic cryogenic sample storage, intelligent retrieval, and RFID-enabled sample lifecycle management; intelligent hospital pharmacy management solutions, including automated drug dispensing systems and smart medicine cabinets; and laboratory consumables, including cryovials, pipette tips, cell culture consumables, and microplates. Qingdao Haier Biomedical Co., Ltd. caters to scientific research institutes, universities, biopharmaceutical enterprises, hospitals, disease prevention and control centers, blood stations, and public health agencies domestically and across more than 140 countries and regions worldwide, collaborating with international bodies such as UNICEF and the World Health Organization. In recent developments, the company has accelerated its strategic transition from a hardware manufacturer into a full-scenario life sciences and digital healthcare solution provider, expanding its offerings in automated bioprocessing, cell and gene therapy (CGT) equipment, and laboratory automation; deepened its presence in laboratory consumables and reagents through targeted capacity expansions and acquisitions; expanded its international localization strategy by establishing regional overseas subsidiaries, technical training centers, and direct logistics hubs across Europe, North America, and the Asia-Pacific; and launched new generations of green energy-saving refrigeration platforms utilizing frequency-conversion and hydrocarbon technologies, automated drug management systems, and AI-enabled digital biobank management platforms.